Miproxifene phosphate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Miproxifene phosphate
Miproxifene phosphate.svg
Clinical data
SynonymsTAT-59; Iproxifene
Routes of
administration
Oral
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC29H36NO5P
Molar mass509.583 g·mol−1
3D model (JSmol)

Miproxifene phosphate (former developmental code name TAT-59) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group[1] that was under development in Japan for the treatment of breast cancer but was abandoned and never marketed.[2][3][4][5] It reached phase III clinical trials for this indication before development was discontinued.[2][5] The drug is a phosphate ester and prodrug of miproxifene (DP-TAT-59) with improved water solubility that was better suited for clinical development.[2][3][6][7] Miproxifene has been found to be 3- to 10-fold as potent as tamoxifen in inhibiting breast cancer cell growth in in vitro models.[2][5][4] It is a derivative of afimoxifene (4-hydroxytamoxifen) in which an additional 4-isopropyl group is present in the β-phenyl ring.[8]

References[edit]

  1. ^ William R. Miller; James N. Ingle (8 March 2002). Endocrine Therapy in Breast Cancer. CRC Press. pp. 53–. ISBN 978-0-203-90983-6.
  2. ^ a b c d http://webcache.googleusercontent.com/search?q=cache:FyhxGXFiLogJ:adisinsight.springer.com/drugs/800000796+&cd=1&hl=en&ct=clnk&gl=us
  3. ^ a b Valentino Stella; Ronald Borchardt; Michael Hageman; Reza Oliyai; Hans Maag; Jefferson Tilley (12 March 2007). Prodrugs: Challenges and Rewards. Springer Science & Business Media. pp. 168–169. ISBN 978-0-387-49782-2.
  4. ^ a b Gary J. Kelloff; Ernest T. Hawk; Caroline C. Sigman (17 August 2008). Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention. Springer. pp. 251–. ISBN 978-1-59259-768-0.
  5. ^ a b c Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 90–. ISBN 978-3-527-62330-3.
  6. ^ Kristian Stromgaard; Povl Krogsgaard-Larsen; Ulf Madsen (19 August 2016). Textbook of Drug Design and Discovery, Fifth Edition. CRC Press. pp. 162–. ISBN 978-1-4987-0279-9.
  7. ^ Hsiu-Chiung Yang; Wu-Kuang Yeh; J. R. McCarthy (22 November 2013). Enzyme Technologies: Pluripotent Players in Discovering Therapeutic Agent. Wiley. pp. 166–. ISBN 978-1-118-73989-1.
  8. ^ Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. pp. 58–60. ISBN 978-3-642-58616-3.

External links[edit]